新辅助化疗不增加根治性膀胱切除术的并发症发生率:一项为期10年的回顾性全国性研究
该研究纳入2005—2014年芬兰全国1427例根治性膀胱切除术中的1385例进行分析,其中231例(16%)接受新辅助化疗、214例(15%)接受至少两个周期化疗。结果显示新辅助化疗未增加根治性膀胱切除术的并发症发生率,90天内总并发症发生率为61%、死亡率为4%。
要点
- 新辅助化疗未增加根治性膀胱切除术的并发症发生率。
- 90天内总并发症发生率为61%,死亡率为4%。
- 新辅助化疗组死亡率为1.9%,单纯根治性膀胱切除术组为4.4%。
核心结论
- 该回顾性全国性研究显示,新辅助化疗不增加根治性膀胱切除术的并发症发生率。
研究设计与样本
- 回顾性研究纳入2005—2014年芬兰全国所有根治性膀胱切除术,共1427例,其中1385例纳入分析。
- 采用基于网络的数据收集平台回顾性收集数据,并发症按Clavien分类记录90天。
- 比较新辅助化疗患者与单纯根治性膀胱切除术患者,采用三个队列和三种方法:整个队列、新辅助化疗时期队列和匹配队列。
- 三个队列均采用简单二元逻辑回归估计比值比(OR),并额外使用倾向评分的多变量分层逻辑模型;匹配队列分析中进行了单因素和校正分析。
主要发现
- 2005—2014年芬兰共实施1427例根治性膀胱切除术,其中1385例纳入分析。
- 新辅助化疗于2008年引入,231例(16%)被分配接受新辅助化疗,214例(15%)接受至少两个周期化疗。
- 90天内61%的患者发生并发症,死亡率为4%(新辅助化疗组为1.9%,单纯根治性膀胱切除术组为4.4%)。
- 在简单二元逻辑回归中,新辅助化疗患者并发症显著更少,但在多变量或倾向评分分析中未观察到这一结果。
- 在匹配队列分析中,未观察到并发症发生率的差异;所有分析均未显示新辅助化疗组并发症发生率更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant chemotherapy (NAC) is underutilized in the treatment of bladder cancer (BC). OBJECTIVE: To investigate the effect of NAC on the risk of surgical complications for radical cystectomy (RC) in a population-based setting. DESIGN, SETTING, AND PARTICIPANTS: All radical cystectomies performed in Finland during 2005-2014 were included in the study. Data were collected retrospectively using a web-based data collection platform. Complications were recorded for 90 d using the Clavien classification. Patients treated with NAC were compared to patients receiving RC alone using three cohorts and approaches: the entire cohort, a neoadjuvant period cohort, and a matched cohort. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: For all three cohorts, odds ratios (ORs) were estimated using simple binary logistic regression. In addition, a multivariable stratified logistic model with propensity score was used. For the matched cohort analysis, both univariate and adjusted analyses were carried out. RESULTS AND LIMITATIONS: During 2005-2014, 1427 RCs were performed in Finland, of which 1385 were included in the analyses. NAC was introduced in 2008, and 231 patients (16%) were assigned to NAC and 214 (15%) received two or more cycles of chemotherapy. Within 90 d, 61% of patients experienced complications and mortality was 4% (1.9% in the NAC group, and 4.4% in the RC-alone group). In simple binary logistic regression, NAC patients had significantly fewer complications, but this was not observed in multivariable or propensity score analyses. In the matched cohort analyses, no differences in complication rates could be observed. None of the analyses demonstrated higher complication rates in the NAC group. CONCLUSIONS: Our retrospective study reports on nationwide use of NAC for BC and demonstrates that NAC does not increase RC morbidity. PATIENT SUMMARY: Chemotherapy given before radical surgery does not increase severe postoperative complications in the treatment of bladder cancer.
引用
- Salminen AP, Koskinen I, Perez IM, et al. Neoadjuvant Chemotherapy Does Not Increase the Morbidity of Radical Cystectomy: A 10-year Retrospective Nationwide Study. Eur Urol Oncol. 2018. PMID: 31158099. doi:10.1016/j.euo.2018.06.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。